The FDA’s recent inclusion of certain GLP-1 receptor agonists on a so-called “Green List” is often portrayed as a regulatory milestone aimed at ensuring safer access to these increasingly popular medications. However, beneath the surface, this policy move may ironically serve to legitimize and even entrench a burgeoning gray market around GLP-1 drugs, with profound implications for patient safety, healthcare equity, and pharmaceutical regulation.
Read more via: https://www.tampafp.com/op-ed-how-the-fdas-green-list-for-glp-1-drugs-fuels-the-gray-market-problem/